Roche acquires AMR focused 'Smarticles' technology company
This article was originally published in Scrip
Executive Summary
Roche Holding AG has acquired GeneWEAVE BioSciences for up to $425m in order to get its hands on the latter''s "Smarticles" technology, which is being developed to help tackle the problem of antibiotic resistance.
You may also be interested in...
Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.